Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279265 | 0.91 | KARS1 (0.53) | KARS1SYK | |
| SCHEMBL2224056 | 0.87 | KARS1 (0.61) | KARS1SYK | |
| SCHEMBL14673942 | 0.84 | KARS1 (0.52) | KARS1SYK | |
| SCHEMBL2228645 | 0.82 | KARS1 (0.73) | KARS1SYK | |
| SCHEMBL14674221 | 0.81 | KARS1 (0.53) | KARS1SYK | |
| SCHEMBL14673724 | 0.81 | KARS1 (0.51) | KARS1SYK | |
| SCHEMBL14673475 | 0.81 | KARS1 (0.55) | KARS1SYK | |
| SCHEMBL2225174 | 0.81 | KARS1 (0.55) | KARS1SYK | |
| SCHEMBL2224901 | 0.81 | KARS1 (0.53) | KARS1SYK | |
| SCHEMBL14680956 | 0.81 | KARS1 (0.52) | KARS1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523952-B1 | OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-03-04 | — | — | EP | claimed |
| CN-102812022-A | Thiazole and oxazole kinase inhibitors | AB SCIENCE | 2012-12-05 | — | — | CN | claimed |
| EP-2523952-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB Science (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086085-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2011-07-21 | — | — | WO | claimed |
| EP-2523952-B1 | OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-03-04 | — | — | EP | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SYK, LTK, MERTK | KARS1 1099/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.